Skip to main content
OpenTrials
Completed

NCT Number: NCT03799172

Echinocandins Versus Azoles for Candidemia Treatment

Candidemia is the most frequent invasive fungal disease in intensive care units (ICUs). It remains a major health concern, considering its attributable mortality up to 40% in critically ill patients. Successful clinical outcome requires early diagnosis and effective antifungal therapy. Guidelines for the treatment of candidemia were published by the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). According to these guidelines, echinocandins are the preferred first-line therapy for candidemia in critically ill patients. Considering the bibliography supporting this statement, the place of triazoles still needs to be defined in candidemia therapeutic arsenal. In this context, we are setting up a retrospective cohort study using Hospital database to compare the efficacy of echinocandins and azoles for the treatment of candidemia in intensive care units.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Candidemia Bacterial Infections and Mycoses Candidiasis Candidiasis, Invasive Fungemia Infections Inflammation Invasive Fungal Infections Mycoses Pathologic Processes Pathological Conditions, Signs and Symptoms Sepsis Systemic Inflammatory Response Syndrome

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospices Civils de Lyon, Hôpital de la Croix-Rousse

Lyon, 69004, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who had a diagnosis of candidemia during ICU stay and were treated with echinocandins or azoles

Exclusion criteria

  • Patients with neutropenia
  • Patients without antifungal treatment
  • Patients who received antifungal therapy for more than two days before candidemia diagnosis
  • Patients receiving liposomal amphotericin b or multiple antifungal agents as first-line therapy
  • Patients who received less than 4 days of antifungal therapy after candidemia diagnosis

Treatment and study plan

Echinocandin treatment

Drug

Patients received echinocandins as a first-line therapy after candidemia diagnosis according to the standard of care

Triazole treatment

Drug

Patients received triazoles as a first-line therapy after candidemia diagnosis according to the standard of care.

Candidemia was defined as at least one blood culture positive for Candida.

Primary outcomes

  1. Comparison of all cause hospital mortality on day 90 between echinocandins and azoles

    Time frame: Mortality on day 90 after antifungal initiation

    Comparison of all cause hospital mortality on day 90 between echinocandins and azoles

Secondary outcomes

  1. Comparison of treatment success on day 30 between echinocandins and azoles.

    Time frame: Treatment success on day 30 after antifungal initiation

    Treatment success is defined as a complete response if the following two criteria were full-filled: survival and resolution of all attributable symptoms and signs of disease, and mycological success (documented clearance of pathogen from the blood).

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Echinocandins Versus Azoles as First-line Therapy for the Treatment of Candidemia in Intensive Care Units

Acronym: AntiCandiTreat

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jan 10, 2019
Registry last updated
Mar 4, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.